Search - tctmd.com

Displaying 61 - 74 of 74

Sort: Relevancy | Date

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

News Conference News ACC 2016

Hints of What’s to Come in New Coronary Revascularization AUC

Caitlin E. Cox

April 12, 2016

News Conference News ACC 2016

CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results

Shelley Wood

April 08, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Conference News ACC 2016

Discrimination Still Runs Rampant for Women in Cardiology

Yael L. Maxwell

April 02, 2016

News Conference News ACC 2015

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

Todd Neale

March 14, 2015

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Conference News ACC 2012

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

L.A. McKeown

March 24, 2012

Advertisement

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Live From Washington: ACC 2017, Day One

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Hints of What’s to Come in New Coronary Revascularization AUC

CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Discrimination Still Runs Rampant for Women in Cardiology

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content